Cardiologists have always wanted a better way to identify heart patients in need of care early in their course of disease. Artificial intelligence may be the tool physicians have been waiting for. 

Listen in to an expert-led discussion of the ALERT Trial and the impact of electronic clinician notifications (ECNs) on the timely treatment of patients with valvular heart disease. While it is estimated that half of patients with symptomatic severe aortic stenosis do not receive timely interventions, the ALERT Trial quantified the impact of clinician alerts in addressing this care gap.

Identifying the signs of severe aortic stenosis is typically a fairly straightforward process for cardiologists. In some cases, however, the patient’s symptoms present in a way that is outside of the norm. 

Prosthesis-patient mismatch (PPM) is the phenomenon that occurs when the effective orifice area of a prosthetic heart valve isn’t adequately sized to meet a patient’s blood flow requirements. More is known today about PPM than ever before—but there is still so much to learn. 

Atrial fibrillation (AFib), the most common heart rhythm disorder, continues to rise globally - it is predicted to affect more than 12 million people in the US by 2030 and almost 18 million people in Europe by 2060. With a growing aging population and an increased prevalence of heart disease, the demand for effective treatments for AFib is higher than ever before. 

Listen in as a general cardiologist, surgeon, and interventionalist delve into the latest evidence—including the Evolut™ TAVR 5-Year Low Risk data and SMART Trial 2-Year update—to guide appropriate treatment decisions for patients with severe symptomatic aortic stenosis.

The late-breaking five-year results of the Evolut Low-Risk Trial presented at ACC.25 showed positive results for the Evolut TAVR system when compared to SAVR.

Howard Herrmann, MD,  MSCAI, Hospital of the University of Pennsylvania, and lead invesigator for the SMART trial, explains details on the 2-year data comparing the Evolut vs. Sapien 3 for TAVR in small annulus patients.